All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the ESH Translational Research Conference, the Lymphoma Hub was pleased to speak with Lukas Frenzel, University Hospital of Cologne, Cologne, DE. We asked, What treatment options are there for patients with chronic lymphocytic leukemia (CLL) who are resistant to both BTK inhibitor (BTKi) and BCL2 inhibitor (BCL2i)?
What treatment options are there for patients with CLL who are resistant to both BTKi and BCL2i?
Frenzel begins by defining double-refractory CLL and a sequential treatment regimen, followed by a discussion on first-line and next-line therapeutic options, stressing the importance of understanding the mode of resistance and further clinical trials. Frenzel then highlights a need to target MCL1, despite toxicities shown in trials. Finally, Frenzel explores cellular therapies, such as CAR T-cell therapy or bispecific antibodies, as ways to overcome resistance.
How might CAR T-cells change the treatment landscape for patients with CLL?
During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak with Julio Delgado, Hospital Clínic de Barcelona, Barcelona, ES. We asked, How might CAR...
What is the most promising new targetable pathway in CLL?
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Alexey Danilov, City of Hope Comprehensive Cancer Center, Duarte, US. We asked,...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox